Literature DB >> 25227869

Safety and efficacy of novel oral anticoagulants in the setting of atrial fibrillation ablation: Is it time to celebrate the "funeral" of warfarin?

Luigi Di Biase1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25227869     DOI： 10.1007/s10840-014-9944-5

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN： 1383-875X            Impact factor:   1.900


× No keyword cloud information.
  16 in total

1.  Nonadherence with INR monitoring and anticoagulant complications.

Authors:  Daniel M Witt; Thomas Delate; Nathan P Clark; David A Garcia; Elaine M Hylek; Walter Ageno; Francesco Dentali; Mark A Crowther
Journal:  Thromb Res       Date:  2013-06-22       Impact factor: 3.944

2.  Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation.

Authors:  Riccardo Cappato; Hugh Calkins; Shih-Ann Chen; Wyn Davies; Yoshito Iesaka; Jonathan Kalman; You-Ho Kim; George Klein; Andrea Natale; Douglas Packer; Allan Skanes; Federico Ambrogi; Elia Biganzoli
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-12-07

3.  Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation.

Authors:  Jin-Seok Kim; Fei She; Krit Jongnarangsin; Aman Chugh; Rakesh Latchamsetty; Hamid Ghanbari; Thomas Crawford; Arisara Suwanagool; Mohammed Sinno; Thomas Carrigan; Robert Kennedy; Wouter Saint-Phard; Miki Yokokawa; Eric Good; Frank Bogun; Frank Pelosi; Fred Morady; Hakan Oral
Journal:  Heart Rhythm       Date:  2012-12-11       Impact factor: 6.343

4.  Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter.

Authors:  Daniel W Kaiser; Megan M Streur; Rangadham Nagarakanti; S Patrick Whalen; Christopher R Ellis
Journal:  J Interv Card Electrophysiol       Date:  2013-04-28       Impact factor: 1.900

5.  Incidence and predictors of periprocedural cerebrovascular accident in patients undergoing catheter ablation of atrial fibrillation.

Authors:  Daniel Scherr; Kavita Sharma; Darshan Dalal; David Spragg; Karuna Chilukuri; Alan Cheng; Jun Dong; Charles A Henrikson; Saman Nazarian; Ronald D Berger; Hugh Calkins; Joseph E Marine
Journal:  J Cardiovasc Electrophysiol       Date:  2009-12

Review 6.  Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation.

Authors:  Partha Sardar; Ramez Nairooz; Saurav Chatterjee; Jørn Wetterslev; Joydeep Ghosh; Wilbert S Aronow
Journal:  Am J Cardiol       Date:  2014-01-15       Impact factor: 2.778

7.  Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation.

Authors:  Gerald V Naccarelli; Riccardo Cappato; Stefan H Hohnloser; Francis E Marchlinski; David J Wilber; Jim Xiang; Changsheng Ma; Susanne Hess; David Wyn Davies; Larry E Fields; Andrea Natale
Journal:  J Interv Card Electrophysiol       Date:  2014-07-09       Impact factor: 1.900

8.  Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation.

Authors:  Mohamed Bassiouny; Walid Saliba; John Rickard; Mingyuan Shao; Albert Sey; Mariam Diab; David O Martin; Ayman Hussein; Maurice Khoury; Bernard Abi-Saleh; Samir Alam; Jay Sengupta; P Peter Borek; Bryan Baranowski; Mark Niebauer; Thomas Callahan; Niraj Varma; Mina Chung; Patrick J Tchou; Mohamed Kanj; Thomas Dresing; Bruce D Lindsay; Oussama Wazni
Journal:  Circ Arrhythm Electrophysiol       Date:  2013-04-03

9.  Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation.

Authors:  Gevorg Stepanyan; Nitish Badhwar; Randall J Lee; Gregory M Marcus; Byron K Lee; Zian H Tseng; Vasanth Vedantham; Jeffrey Olgin; Melvin Scheinman; Edward P Gerstenfeld
Journal:  J Interv Card Electrophysiol       Date:  2014-03-19       Impact factor: 1.900

10.  Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay.

Authors:  Kimitake Imamura; Akihiro Yoshida; Asumi Takei; Koji Fukuzawa; Kunihiko Kiuchi; Kaoru Takami; Mitsuru Takami; Mitsuaki Itoh; Ryudo Fujiwara; Atsushi Suzuki; Tomoyuki Nakanishi; Soichiro Yamashita; Akinori Matsumoto; Ken-Ichi Hirata
Journal:  J Interv Card Electrophysiol       Date:  2013-04-14       Impact factor: 1.900
View more
  2 in total

Review 1.  A Patient With Asymptomatic Cerebral Lesions During AF Ablation: How Much Should We Worry?

Authors:  Giovanni B Forleo; Domenico G Della Rocca; Carlo Lavalle; Massimo Mantica; Lida P Papavasileiou; Valentina Ribatti; Germana Panattoni; Luca Santini; Andrea Natale; Luigi Di Biase
Journal:  J Atr Fibrillation       Date:  2016-02-29

2.  Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation.

Authors:  Peter A Noseworthy; Xiaoxi Yao; Abhishek J Deshmukh; Holly Van Houten; Lindsey R Sangaralingham; Konstantinos C Siontis; Jonathan P Piccini; Samuel J Asirvatham; Paul A Friedman; Douglas L Packer; Bernard J Gersh; Nilay D Shah
Journal:  J Am Heart Assoc       Date:  2015-11-05       Impact factor: 5.501
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.